Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 461 results for "Victoza"

New Study With Victoza® (Liraglutide) Showed Improvements in Blood Glucose Control in Adults With Type 2 Diabetes Who Fasted During Ramadan
AndhraNews.net

Novo Drug Works During Ramadan Fast

Adults with type 2 diabetes treated with Novo Nordisk's Victoza ® , in combination with metformin, experienced similar improvements in blood glucose control while fasting during the four weeks of Ramadan compared with sulfonylurea (SU) plus ... Nordic Life Science, 3 weeks ago
[x]  

20 images for Victoza

Diabetes.co.uk, 6 days ago
Pharma Letter, 1 week ago
Diabetes.co.uk, 2 weeks ago
SearchBug, 3 weeks ago
Diabetes.co.uk, 1 month ago
Seeking Alpha, 1 month ago
Diabetes.co.uk, 1 month ago
Milwaukee Journal Sentinel, 2 months ago
Pharma Letter, 5 months ago
diaTribe, 5 months ago
Review Seeker

ELI LILLY : Study: Once-Weekly Trulicity dulaglutide Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® liraglutide in Japanese Patients...

Study: Once-Weekly Trulicity dulaglutide Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® liraglutide in Japanese Patients after 52 weeks By a News Reporter-Staff News Editor at Diabetes Week -- Results from a new study of ...
 4 Traders2 weeks ago Study: Once-Weekly Trulicity (dulaglutide) Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® (liraglutide) in Japanese Patients after 52 weeks  Pharma Voice3 weeks ago Study: Once-Weekly Trulicity(TM) (dulaglutide) Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® (liraglutide) in Japanese Patients after 52 weeks  Individual.com3 weeks ago Study: Once-Weekly Trulicity??? (dulaglutide) Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza?? (liraglutide) in Japanese Patients after 52 weeks  Review Seeker3 weeks ago
[x]  

Novo Nordisk Reveals New Findings from Additional Studies - Analyst Blog

Novo Nordisk A/S NVO announced new data from a couple of studies on its approved products, Xultophy and Victoza, during the weekend. Firstly, Novo Nordisk reported that the company's type II diabetes drug Xultophy led to a statistically ...
 Yahoo! Finance3 weeks ago
[x]  

Novo Nordisk studies diabetes drug's use in fatty liver disease

COPENHAGEN, May 18 (Reuters) - Novo Nordisk is looking into recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease, a hot area for pharmaceutical development.Research from Britain's ...
 London South East1 month ago Novo Nordisk weighs diabetes drug's use in fatty liver disease  Reuters India1 month ago REFILE-Novo Nordisk weighs diabetes drug's use in fatty liver disease  London South East1 month ago
[x]  

Warning: Don't Share Insulin Pens

If you use insulin pens or take other injected diabetes medications (such as Symlin, Victoza, or Byetta), don't share your medication pen with anyone else—even if youve attached a new needle. Blood can get stuck inside the pen from previous use ...
 Diabetes Forecast2 days ago
Seeking Alpha

Novo Nordisk's Victoza gives superior blood glucose control in Ramadan compared to sulfonylurea

Danish insulin giant Novo Nordisk has presented results at the American Diabetes Association meeting… In order to access this content you need to be logged into the site and have an active subscription or trial subscription. Please login , take ...
 Pharma Letter3 weeks ago Expect Novo Nordisk To Commit To Their Late-Stage Diabetes Pill Development Soon  Seeking Alpha1 week ago Novo Nordisk launches diabetes combination  Pharmafile3 weeks ago Novo Nordisk And Its Promising Diabetes Drugs  Seeking Alpha1 month ago

ViewPoints: Novo Nordisk broadens Victoza life cycle management strategy

You attempted to read ViewPoints , exclusive content for FirstWord Pharma PLUS members. You currently are not registered for any FirstWord Pharma services. To gain instant access to ViewPoints plus additional enhanced content and features, please ...
 FirstWord Pharma3 weeks ago

Scottish Medicines Consortium: liraglutide (Victoza)

following a full submission liraglutide (Victoza®) is accepted for use within NHS Scotland. Indication under review : For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with basal insulin ...
 FirstWord Pharma1 month ago Scottish Medicines Consortium approves seven drugs  Pharmafile1 month ago Scotland yes for UC and blood cancer meds  Pharma Field1 month ago SMC accepts seven new medicines for use in NHS Scotland  European Pharmaceutical Review1 month ago
Lawyers & Settlements

Possible Lawsuit: Victoza Side Effects - Pancreatic and Thyroid Cancer

In March 2013 the US Food and Drug Administration (FDA) announced results of a study suggesting Victoza side effects could include an increased risk of Victoza pancreatitis. Victoza has already reportedly been linked in animal studies to an ...
 Lawyers & Settlements1 month ago
MedPage Today

Published Results Confirm Weight Loss With Saxenda (CME/CE)

Action Points Note that this randomized trial of liraglutide found that it was superior to placebo in terms of weight loss at 56 weeks. Be aware that significantly more patients withdrew from the liraglutide group due to adverse events compared ...
 MedPage Today6 hours ago GI Events Do Not Explain Weight Loss With Saxenda (CME/CE)  MedPage Today1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Victoza
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less